Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) shares dropped 4.8% on Monday . The stock traded as low as $2.61 and last traded at $2.77. Approximately 2,070,560 shares changed hands during trading, an increase of 110% from the average daily volume of 987,783 shares. The stock had previously closed at $2.91.
Phio Pharmaceuticals Stock Performance
The company’s 50-day moving average is $2.48 and its two-hundred day moving average is $3.02.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Further Reading
- Five stocks we like better than Phio Pharmaceuticals
- Where to Find Earnings Call Transcripts
- Avient Stock: Manufacturing Play With Double-Digit Upside
- The Most Important Warren Buffett Stock for Investors: His Own
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
- Conference Calls and Individual Investors
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
